Teva Can't Swap Out Expert In HIV Drug Patent Trial

Law360, New York (February 7, 2013, 5:14 PM EST) -- A New York federal judge on Wednesday shot down Teva Pharmaceuticals USA Inc.’s bid to switch out its expert witness for its upcoming trial versus Gilead Sciences Inc. over patents for HIV drugs, finding substituting an expert at this stage would be unfair to Gilead.

U.S. District Judge Richard J. Sullivan rejected Teva's request to bring in a new expert for the trial over a recent Federal Circuit opinion finding Dr. Ashim Mitra was less than truthful in another Teva suit, saying he could find no...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.